On the other hand, there was no statistically significant OS difference (8.3 vs. 7.4 months, HR 0.78, and p = 0.4) in the subgroup of patients with 40–69% of tumour cells positive for CLDN18.2. The gene discussed is CLDN18; the disease is neoplasm.